Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-10-2019 | Original Paper

Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders

Authors: Sherif M. Gohar, Ingrid Dieset, Nils Eiel Steen, Ragni H. Mørch, Trude S. Iversen, Vidar M. Steen, Ole A. Andreassen, Ingrid Melle

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2019

Abstract

Although the relationship between positive and negative symptoms of psychosis and dyslipidemia has been thoroughly investigated in recent studies, the potential link between depression and lipid status is still under-investigated. We here examined the association between lipid levels and depressive symptomatology in patients with psychotic disorders, in addition to their possible inflammatory associations. Participants (n = 652) with the following distribution: schizophrenia, schizophreniform and schizoaffective disorder (schizophrenia group, n = 344); bipolar I, II, NOS, and psychosis NOS (non-schizophrenia group, n = 308) were recruited consecutively from the Norwegian Thematically Organized Psychosis (TOP) Study. Clinical data were obtained by Positive and Negative Syndrome Scale (PANSS), and Calgary Depression Scale for Schizophrenia (CDSS). Blood samples were analyzed for total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), C-reactive protein (CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), and interleukin 1 receptor antagonist (IL-1Ra). After adjusting for age, gender, BMI, smoking, and dyslipidemia-inducing antipsychotics, TC and LDL scores showed significant associations with depression [β = 0.13, p = 0.007; β = 0.14, p = 0.007], and with two inflammatory markers: CRP [β = 0.14, p = 0.007; β = 0.16, p = 0.007] and OPG [β = 0.14, p = 0.007; β = 0.11, p = 0.007]. Total model variance was 17% for both analyses [F(12, 433) = 8.42, p < 0.001; F(12, 433) = 8.64, p < 0.001]. Current findings highlight a potential independent role of depression and inflammatory markers, CRP and OPG in specific, in the pathophysiology of dyslipidemia in psychotic disorders.

Saari K, Jokelainen J, Veijola J, Koponen H, Jones PB, Savolainen M, Jarvelin MR, Lauren L, Isohanni M, Lindeman S (2004) Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatr Scand 110(4):279–285. https://doi.org/10.1111/j.1600-0447.2004.00358.x CrossRefPubMed

Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia. Br J Psychiatry 177:212–217CrossRefPubMed

Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Ann Rev Clin Psychol 10:425–448. https://doi.org/10.1146/annurev-clinpsy-032813-153657 CrossRef

Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D (2017) Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. Schizophr Res 190:18–27. https://doi.org/10.1016/j.schres.2017.03.031 CrossRefPubMed

Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O’Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, International Consortium for Blood Pressure G, Diabetes Genetics R, Meta-analysis C, Psychiatric Genomics Consortium Schizophrenia Working G, Roddey JC, McEvoy LK, Desikan RS, Dale AM (2013) Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Human Genet 92 (2):197–209. https://doi.org/10.1016/j.ajhg.2013.01.001 CrossRef

Solberg DK, Bentsen H, Refsum H, Andreassen OA (2016) Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study. BMC Psychiatry 16:299. https://doi.org/10.1186/s12888-016-1006-3 CrossRefPubMedPubMedCentral

Kahl KG, Greggersen W, Schweiger U, Cordes J, Balijepalli C, Lösch C, Moebus S (2012) Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 262(4):313–320. https://doi.org/10.1007/s00406-011-0277-4 CrossRefPubMed

Persons JE, Fiedorowicz JG (2016) Depression and serum low-density lipoprotein: a systematic review and meta-analysis. J Affect Disord 206:55–67. https://doi.org/10.1016/j.jad.2016.07.033 CrossRefPubMedPubMedCentral

Parekh A, Smeeth D, Milner Y, Thure S (2017) The role of lipid biomarkers in major depression. Healthcare (Basel Switz) 5 (1). https://doi.org/10.3390/healthcare5010005

10.

Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W (2001) Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58(3):221–227CrossRefPubMed

11.

Wysokinski A, Strzelecki D, Kloszewska I (2015) Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab Syndrome 9(3):168–176. https://doi.org/10.1016/j.dsx.2015.04.004 CrossRef

12.

Gjerde PB, Dieset I, Simonsen C, Hoseth EZ, Iversen T, Lagerberg TV, Lyngstad SH, Morch RH, Skrede S, Andreassen OA, Melle I, Steen VM (2017) Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. Schizophr Res. https://doi.org/10.1016/j.schres.2017.10.042 CrossRefPubMed

13.

Mørch RH, Dieset I, Færden A, Hope S, Aas M, Nerhus M, Gardsjord ES, Joa I, Morken G, Agartz I, Aukrust P, Djurovic S, Melle I, Ueland T, Andreassen OA (2016) Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology 67:189–197. https://doi.org/10.1016/j.psyneuen.2016.02.011 CrossRefPubMed

14.

Miller BJ, Goldsmith DR (2017) Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions. Neuropsychopharmacology 42(1):299–317. https://doi.org/10.1038/npp.2016.211 CrossRefPubMed

15.

Kohler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctot KL, Carvalho AF (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135(5):373–387. https://doi.org/10.1111/acps.12698 CrossRefPubMed

16.

Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanadis C, Papavassiliou AG (2011) Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Design 17(37):4132–4146CrossRef

17.

Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, Maisano C, Jones L, Murrah NV, Vaccarino V (2008) Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 64(10):896–900. https://doi.org/10.1016/j.biopsych.2008.05.019 CrossRefPubMedPubMedCentral

18.

Rethorst CD, Bernstein I, Trivedi MH (2014) Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009–2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry 75(12):e1428-1432. https://doi.org/10.4088/JCP.14m09009 CrossRef

19.

Nybo M, Rasmussen LM (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 159(5):603–608. https://doi.org/10.1530/eje-08-0554 CrossRefPubMed

20.

Hope S, Melle I, Aukrust P, Agartz I, Lorentzen S, Steen NE, Djurovic S, Ueland T, Andreassen OA (2010) Osteoprotegerin levels in patients with severe mental disorders. J Psychiatry Neurosci 35(5):304–310. https://doi.org/10.1503/jpn.090088 CrossRefPubMedPubMedCentral

21.

Nerhus M, Berg AO, Kvitland LR, Dieset I, Hope S, Dahl SR, Weibell MA, Romm KL, Faerden A, Andreassen OA, Melle I (2016) Low vitamin D is associated with negative and depressive symptoms in psychotic disorders. Schizophr Res 178(1–3):44–49. https://doi.org/10.1016/j.schres.2016.08.024 CrossRefPubMed

22.

Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, Gardsjord E, Morch R, Agartz I, Melle I, Ueland T, Spigset O, Andreassen OA (2017) Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry 18(6):471–482. https://doi.org/10.1080/15622975.2016.1245441 CrossRefPubMed

23.

First MBSR., Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P) Biometrics Research. New York State Psychiatric Institute, New York

24.

Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276. https://doi.org/10.1093/schbul/13.2.261 CrossRef

25.

Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3(4):247–251. https://doi.org/10.1016/0920-9964(90)90005-R CrossRefPubMed

26.

Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, Aukrust P, Røssberg J-I, Andreassen OA (2012) Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res 140(1):169–174. https://doi.org/10.1016/j.schres.2012.06.040 CrossRefPubMed

27.

Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, Agartz I, Aukrust P, Andreassen OA (2013) Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 145(1):36–42. https://doi.org/10.1016/j.schres.2012.12.023 CrossRef

28.

Goncalves P, Araujo JR, Martel F (2015) Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 25(1):1–16. https://doi.org/10.1016/j.euroneuro.2014.11.008 CrossRefPubMed

29.

Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347. https://doi.org/10.1002/wps.20252 CrossRefPubMedPubMedCentral

30.

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126. https://doi.org/10.1038/nrendo.2011.156 CrossRefPubMed

31.

Addington D, Addington J, Maticka-Tyndale E (1994) Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 11(3):239–244CrossRefPubMed

32.

Sands JR, Harrow M (1999) Depression during the longitudinal course of schizophrenia. Schizophr Bull 25(1):157–171CrossRefPubMed

33.

Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E (2007) Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia. Am J Geriatric Psychiatry 15(12):1005–1014. https://doi.org/10.1097/JGP.0b013e3180a725ec CrossRef

34.

Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P (2003) Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 108(4):297–303CrossRefPubMed

35.

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24 (2):e13-18. https://doi.org/10.1161/01.atv.0000111245.75752.c6 CrossRefPubMed

36.

Akbaraly TN, Kivimaki M, Brunner EJ, Chandola T, Marmot MG, Singh-Manoux A, Ferrie JE (2009) Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes care 32(3):499–504. https://doi.org/10.2337/dc08-1358 CrossRefPubMedPubMedCentral

37.

Skilton MR, Moulin P, Terra JL, Bonnet F (2007) Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 62(11):1251–1257. https://doi.org/10.1016/j.biopsych.2007.01.012 CrossRefPubMed

38.

Viinamaki H, Heiskanen T, Lehto SM, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Saharinen T, Haatainen K, Hintikka J (2009) Association of depressive symptoms and metabolic syndrome in men. Acta Psychiatr Scand 120(1):23–29. https://doi.org/10.1111/j.1600-0447.2008.01333.x CrossRefPubMed

39.

Suttajit S, Pilakanta S (2013) Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. Neuropsychiatr Dis Treat 9:941–946. https://doi.org/10.2147/NDT.S47450 CrossRefPubMedPubMedCentral

40.

Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB (2012) Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35(5):1171–1180. https://doi.org/10.2337/dc11-2055 CrossRefPubMedPubMedCentral

41.

Mezuk B, Eaton WW, Albrecht S, Golden SH (2008) Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31(12):2383–2390. https://doi.org/10.2337/dc08-0985 CrossRefPubMedPubMedCentral

42.

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG (2010) Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 67(3):220–229. https://doi.org/10.1001/archgenpsychiatry.2010.2 CrossRefPubMed

43.

Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155(1–3):101–108. https://doi.org/10.1016/j.schres.2014.03.005 CrossRef

44.

Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(9468):1415–1428. https://doi.org/10.1016/s0140-6736(05)66378-7 CrossRefPubMed

45.

Martinac M, Pehar D, Karlovic D, Babic D, Marcinko D, Jakovljevic M (2014) Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder. Acta Clin Croat 53(1):55–71PubMed

46.

Toffoli B, Fabris B, Bartelloni G, Bossi F, Bernardi S (2016) Dyslipidemia and diabetes increase the OPG/TRAIL ratio in the cardiovascular system. Mediat Inflamm 2016:6529728. https://doi.org/10.1155/2016/6529728 CrossRef

47.

Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism Clin Exp 54(1):49–54. https://doi.org/10.1016/j.metabol.2004.08.005 CrossRef

48.

Kadoglou NP, Kottas G, Lampropoulos S, Vitta I, Liapis CD (2014) Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Investig 34(3):165–171. https://doi.org/10.1007/s40261-013-0157-y CrossRefPubMed

49.

Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, Aukrust P, Andreassen OA (2011) Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatric Res 45(12):1608–1616. https://doi.org/10.1016/j.jpsychires.2011.08.003 CrossRef

50.

Siris SG (2000) Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry 157(9):1379–1389. https://doi.org/10.1176/appi.ajp.157.9.1379 CrossRefPubMed

51.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962. https://doi.org/10.1016/s0140-6736(13)60733-3 CrossRefPubMed

52.

Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K, Andersson U, Bjorkhem I, Bergmann Kv K, Fassbender K (2004) High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69(6):431–438. https://doi.org/10.1016/j.steroids.2004.03.012 CrossRefPubMed

53.

Tomasik J, Rahmoune H, Guest PC, Bahn S (2016) Neuroimmune biomarkers in schizophrenia. Schizophr Res 176(1):3–13. https://doi.org/10.1016/j.schres.2014.07.025 CrossRefPubMed

Title: Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders
Authors: Sherif M. Gohar
Ingrid Dieset
Nils Eiel Steen
Ragni H. Mørch
Trude S. Iversen
Vidar M. Steen
Ole A. Andreassen
Ingrid Melle
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2019
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0897-z

At a glance: The STEP trials

Springer Medicine

Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort

Cerebral blood flow responses during prosaccade and antisaccade preparation in major depression

Is (S)-norketamine an alternative antidepressant for esketamine?

Prevalence of seasonal depression in a prospective cohort study

A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation

Relationship between VEGF-related gene polymorphisms and brain morphology in treatment-naïve patients with first-episode major depressive disorder